{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:02:55Z","timestamp":1785322975241,"version":"3.55.0"},"reference-count":46,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Einstein (S\u00e3o Paulo)"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>ABSTRACT Objective: To compare efficacy and safety of vancomycin versus teicoplanin in patients with proven or suspected infection. Methods: Data Sources: Cochrane Renal Group's Specialized Register, CENTRAL, MEDLINE, EMBASE, nephrology textbooks and review articles. Inclusion criteria: Randomized controlled trials in any language comparing teicoplanin to vancomycin for patients with proven or suspected infection. Data extraction: Two authors independently evaluated methodological quality and extracted data. Study investigators were contacted for unpublished information. A random effect model was used to estimate the pooled risk ratio (RR) with 95% confidence interval (CI). Results: A total of 24 studies (2,610 patients) were included. The drugs had similar rates of clinical cure (RR: 1.03; 95%CI: 0.98-1.08), microbiological cure (RR: 0.98; 95%CI: 0.93-1.03) and mortality (RR: 1.02; 95%CI: 0.79-1.30). Teicoplanin had lower rates of skin rash (RR: 0.57; 95%CI: 0.35-0.92), red man syndrome (RR: 0.21; 95%CI: 0.08-0.59) and total adverse events (RR: 0.73; 95%CI: 0.53-1.00). Teicoplanin reduced the risk of nephrotoxicity (RR: 0.66; 95%CI: 0.48-0.90). This effect was consistent for patients receiving aminoglycosides (RR: 0.51; 95%CI: 0.30-0.88) or having vancomycin doses corrected by serum levels (RR: 0.22; 95%CI: 0.10-0.52). There were no cases of acute kidney injury needing dialysis. Limitations: Studies lacked a standardized definition for nephrotoxicity. Conclusions: Teicoplanin and vancomycin are equally effective; however the incidence of nephrotoxicity and other adverse events was lower with teicoplanin. It may be reasonable to consider teicoplanin for patients at higher risk for acute kidney injury.<\/jats:p>","DOI":"10.1590\/s1679-45082011ao2020","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T23:05:03Z","timestamp":1440889503000},"page":"265-282","source":"Crossref","is-referenced-by-count":14,"title":["Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection"],"prefix":"10.1590","volume":"9","author":[{"given":"Diogo Diniz Gomes","family":"Bugano","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo \u2013 USP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Biasi","family":"Cavalcanti","sequence":"additional","affiliation":[{"name":"Hospital do Cora\u00e7\u00e3o \u2013 HCor, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson Roman","family":"Goncalves","sequence":"additional","affiliation":[{"name":"Universidade da Regi\u00e3o de Joinville \u2013 UNIVILLE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Salvini de","family":"Almeida","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo - USP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli\u00e9zer","family":"Silva","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein \u2013 HIAE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/216507990705500504","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus: an ever-emerging epidemic","volume":"55","author":"Bubacz MR","year":"2007","journal-title":"AAOH"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1086\/516664","article-title":"Acquisition of methicillin-resistant Staphylococcus aureus in the acute care setting: incidence and risk factors","volume":"28","author":"Rioux C","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajic.2004.10.001","article-title":"National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004","volume":"32","year":"2004","journal-title":"Am J Infect Control"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff H","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/BF02026127","article-title":"Methicillin-resistant Staphylococcus aureus in Europe","volume":"13","author":"Voss A","year":"1994","journal-title":"EurJ Clin Microbiol Infect Dis"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1345\/aph.1H414","article-title":"Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus","volume":"41","author":"Maclayton DO","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/37.2.209","article-title":"The comparative efficacy and safety of teicoplanin and vancomycin","volume":"37","author":"Wood MJ","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref8","first-page":"376","article-title":"Vancomycin ototoxicity and nephrotoxicity","volume":"3","author":"Bailie GR","year":"1988","journal-title":"A review. Med Toxicol Adverse Drug Exp"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/j.1875-9114.1986.tb03471.x","article-title":"Vancomycin: an update","volume":"6","author":"Cheung RP","year":"1986","journal-title":"Pharmacotherapy"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1001\/archinte.1989.00390080053013","article-title":"Mild nephrotoxicity associated with vancomycin use","volume":"149","author":"Downs NJ","year":"1989","journal-title":"Arch Intern Med"},{"issue":"19","key":"ref11","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat LK","year":"2006","journal-title":"Arch Intern Med"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1179\/joc.1997.9.6.420","article-title":"Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?","volume":"9","author":"Kralovicov\u00e1 K","year":"1997","journal-title":"J Chemother"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1179\/joc.2000.12.4.326","article-title":"Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia","volume":"12","author":"Sidi V","year":"2000","journal-title":"J Chemother"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1542\/peds.103.4.e48","article-title":"Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study","volume":"103","author":"Bhatt-Mehta V","year":"1999","journal-title":"Pediatrics"},{"issue":"3","key":"ref15","first-page":"231","article-title":"Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients","volume":"84","author":"V\u00e1zquez L","year":"1999","journal-title":"Haematologica"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea","volume":"22","author":"Wenisch C","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"Rybak MJ","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1128\/AAC.36.10.2204","article-title":"Subcellular localization of tobramycin and vancomycin given alone and in combination in proximal tubular cells, determined by immunogold labeling","volume":"36","author":"Beauchamp D","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-3565(25)20414-1","article-title":"Mechanism of vancomycin transport in the kidney: studies in rabbit renal brush border and basolateral membrane vesicles","volume":"259","author":"Sokol PP","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/AAC.34.1.139","article-title":"Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats","volume":"34","author":"Beauchamp D","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref21","first-page":"103","article-title":"Vancomycin toxicity. What is the evidence for dose dependency?","volume":"13","author":"Duffull SB","year":"1994","journal-title":"Adverse Drug React Toxicol Rev"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/sim.4780101105","article-title":"A general parametric approach to the metaanalysis of randomized clinical trials","volume":"10","author":"Whitehead A","year":"1991","journal-title":"Stat Med"},{"key":"ref23","series-title":"The Cochrane Collaboration","author":"Higgins JP","year":"2011"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"ref25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JPT","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"ref26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","journal-title":"BMJ"},{"issue":"7382","key":"ref27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman DG","year":"2003","journal-title":"BMJ"},{"issue":"20","key":"ref28","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson SG","year":"1999","journal-title":"Stat Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0609.1993.tb01901.x","article-title":"Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients","volume":"54","author":"Chow AW","year":"1993","journal-title":"Eur J Haematol Suppl"},{"issue":"8","key":"ref30","first-page":"515","article-title":"[Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes]","volume":"196","author":"Figuera A","year":"1996","journal-title":"Rev Clin Esp"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.35.3.451","article-title":"Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts","volume":"35","author":"Van der Auwera P","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1128\/AAC.38.9.2041","article-title":"Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program","volume":"38","author":"Menichetti F","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/AAC.35.1.79","article-title":"Failure of treatment with teicoplanin at 6 milligrams\/kilogram\/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon","volume":"35","author":"Gilbert DN","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1128\/AAC.36.6.1204","article-title":"Absence of \u201cred man syndrome\u201d in patients being treated with vancomycin or high-dose teicoplanin","volume":"36","author":"Rybak MJ","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"ref35","first-page":"165","article-title":"A randomized study comparing clinical efficacy, of ceftazidime plus aztreonam plus teieoptanm or vancomycin containmg regimen in febrile granulocytopenic patients","volume":"10","author":"Choi J","year":"1992","journal-title":"J Korean Soc Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0924-8579(94)90049-3","article-title":"A critical review of the dosage of teicoplanin in Europe and the USA","volume":"4","author":"Wilson AP","year":"1994","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/infdis\/159.5.938","article-title":"Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography","volume":"159","author":"Cremieux AC","year":"1989","journal-title":"J Infect Dis"},{"key":"ref38","series-title":"Marion Merrel Dow - USA Protocol 014. Data on file, Marion Merrell Dow"},{"issue":"7454","key":"ref39","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins D","year":"2004","journal-title":"BMJ"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00075198-200212000-00005","article-title":"Developing a consensus classification system for acute renal failure","volume":"8","author":"Kellum JA","year":"2002","journal-title":"Curr Opin Crit Care"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta RL","year":"2007","journal-title":"Crit Care"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure -definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo R","year":"2004","journal-title":"Crit Care"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/jac\/dki004","article-title":"Safety and efficacy of glycopeptide antibiotics","volume":"55","author":"Finch RG","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0924-8579(95)00002-P","article-title":"Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial","volume":"5","author":"Neville LO","year":"1995","journal-title":"Int J Antimicrob Agents"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/21.suppl_A.81","article-title":"Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results","volume":"21","author":"Hermans YPS","year":"1988","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijantimicag.2008.05.012","article-title":"Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis","volume":"32","author":"Brink AJ","year":"2008","journal-title":"Int J Antimicrob Agents"}],"container-title":["Einstein (S\u00e3o Paulo)"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/eins\/v9n3\/1679-4508-eins-9-3-0265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:59:51Z","timestamp":1748595591000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1679-45082011000300265&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1679-45082011000300265"],"URL":"https:\/\/doi.org\/10.1590\/s1679-45082011ao2020","relation":{},"ISSN":["1679-4508"],"issn-type":[{"value":"1679-4508","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}